ADA (Adenosine Deaminase, Adenosine Aminohydrolase) (Biotin)

Adenosine deaminase (ADA; EC 3.5.4.4, human 393aa; mol wt 32-33kD, pI=4.85) catayzes deaminaiton of adenosine to inosine. ADA is found primarily in cytosol. It has also been located at the cell mmbrane and implicated in the availability of adenosine. It is ubiquitous in mammalian tissue, and deficiency in adenosine deaminase has been associated with severe combined immunodeficiency disease. The enzyme has been tested as a target for gene therapy treatments of this disease

There is a common allele, ADA2, also known as the ADA 2 allozyme. It is associated with the reduced metabolism of adenosine to inosine. It specifically enhances deep sleep and slow-wave activity (SWA) during sleep. Defects in ADA are a cause of autosomal recessive severe combined immunodeficiency SCID, a congenital disorder characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Onset is during infancy. Less often, immune dysfunction develops later in childhood (delayed) and in a few cases ADA deficiency has been diagnosed in chronically ill teenagers and adults (late or adult onset). Population and newborn screening programs have also identified several healthy individuals with normal immunity, mainly in African descent, who have partial ADA deficiency. ADA deficiency accounts for about one-half of cases of autosomal recessive SCID. In hereditary hemolytic anemia, ADA in erythrocytes increases 50-70 times.

Applications:
Suitable for use in ELISA. Western Blot, though not tested, may potentially be used as an application. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.